AC Immune Expands Lilly Tau Collaboration — CHF 10M Upfront With 1.7B Milestone Ceiling

Event Analysis

As reported by GlobeNewswire and confirmed via SEC 6-K filing, AC Immune SA (NASDAQ: ACIU) announced on April 7, 2026, an amendment to its existing Morphomer® Tau license and collaboration agreement with Eli Lilly and Company (NYSE: LLY). The deal, originally struck in 2018, has now been expanded to cover new lead Tau Morphomer® candidates and back-up compounds — oral small molecules engineered to cross the blood-brain barrier and inhibit intracellular Tau pathology linked to Alzheimer's disease and other tauopathies.

The financial structure is notable: AC Immune receives an immediate CHF 10 million (~$12.5M USD) upfront payment, an undisclosed milestone upon Phase 1 first dosing, and access to a total potential value exceeding CHF 1.7 billion in development, regulatory, and commercial milestones, plus low double-digit tiered royalties. IND-enabling studies are set to commence in H1 2026. According to FierceBiotech, this mirrors the structure of the 2020 amendment which also carried a CHF 10M milestone, suggesting a deliberate, staged de-risking approach by Lilly as the asset matures toward the clinic.

For ACIU, this is a transformative non-dilutive cash event for a company with a market cap typically below $500M. The amendment validates AC Immune's Morphomer platform at a time when the broader Alzheimer's field is shifting from amyloid-only approaches toward combination and tau-targeting strategies. Lilly — already a dominant force in the AD space via its approved amyloid therapy Kisunla (donanemab) — is strategically hedging across multiple pathological targets. This strategic corporate partnership reflects the industry's growing conviction that tau inhibition represents the next major therapeutic frontier.

What This Means for Traders

For ACIU, the near-term trading case is straightforwardly bullish: non-dilutive cash reduces financing risk, Lilly's continued commitment validates the science, and biotech stocks of this scale routinely see outsized percentage moves on partnership catalysts. However, traders should note the asset remains preclinical-stage with all associated binary risks — Phase 1 initiation is the next hard catalyst, and failure rates in Alzheimer's trials remain historically high.

For LLY, the impact is immaterial at its current scale. According to live market data, LLY is trading at $919.70, down 0.73% on the day, with an intraday range of $898.75–$930.74 — the AD pipeline expansion is positive for long-term portfolio depth but moves no near-term needle for a company of Lilly's market capitalization. Traders tracking LLY's broader momentum may find more relevance in its recently FDA-approved oral weight-loss pill Foundayo. Broad indices like the NASDAQ 100 Index and S&P 500 Index are effectively unaffected by this event.

Sector-watchers should monitor sympathy moves in tau/Alzheimer's-adjacent names. Peers such as AstraZeneca PLC and Regeneron Pharmaceuticals, Inc. have exposure to neurodegeneration pipelines and could see marginal sentiment lifts as deal activity confirms investor appetite for the space. Volatility in ACIU will likely be elevated around Phase 1 initiation — check open interest and volume on CoinUnited.io for confirmation signals before scaling positions.

Trade Eli Lilly and Company on CoinUnited.io

Trade LLY with up to 800xx leverage → | Create Free Account